GB2169892A - Piperazine derivatives - Google Patents
Piperazine derivatives Download PDFInfo
- Publication number
- GB2169892A GB2169892A GB08501625A GB8501625A GB2169892A GB 2169892 A GB2169892 A GB 2169892A GB 08501625 A GB08501625 A GB 08501625A GB 8501625 A GB8501625 A GB 8501625A GB 2169892 A GB2169892 A GB 2169892A
- Authority
- GB
- United Kingdom
- Prior art keywords
- piperazine
- ethanol
- addition salts
- alkanol
- dioxolane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The compound of the formula <IMAGE> and its salts are cardiovascular agents and antihistamines.r
Description
SPECIFICATION
A piperazine derivative, a process for preparing it and pharmaceutical composition
The present invention relates to a piperazine derivative of the formula (I):
and the non-toxic addition salts thereof.
The compound of the present invention may be prepared according to the following scheme:
wherein X, in the starting coompound of the general formula (III), is chlorine or bromine.
The reaction between N-mono-(4,4'-difluorobenzhydryl)piperazine (II) and 2-(3-halopropyl)-2-phenyl-1,3-dioxolane (III) is conveniently carried out in a medium constituted by an alkanol having from 1 to 4 carbon atoms, preferably ethanol, and in the presence of a base selected from an alkaline/alkaline earth carbonate or bicarbonate, preferably sodium bicarbonate, under reflux.
The compound of the present invention like its non fluorine analogue, which was described in
Spanish Patent No. 514 340, has strong properties on blood stream and thus it is a useful vaso-active, antiarrhythmic and hypotensor agent. Furthermore, the compound of the present invention has proved to possess an additional antihistamic effect higher than that of its non fluorine analogue. In Table 1 the parameter of anti-histamine activity expressed as EDso (mol/liter) is comparatively tabulated for the compound of formula (I) as well as its analogue (Spanish
Patent No. 514 340) versus Cinnarizine and Flunarizine.
TABLE 1
Compound t-- f- ED50 (mol/liter) Example 1 - R = F 1.5 x Spanish Pat. 514340 R = H 3.5 x Cinnarizine -- 1.7 x Flurarizine -- 2.7 x The anti-histamine activity was tested in an isolate of guinea-pig ileum suspended in a Tyrode bath at 32-35"C according to a protocol described by R.A. Turner (Screening Methods in
Pharmacology. Academic Press, 1965, pp. 43).
The compound of the present invention and the non-toxic addition salts thereof mixed with pharmaceutically acceptable carriers can be administered by the oral route in the form of tablets, capsules, syrup, solution, etc., by injectable route and by rectal route, at daily doses ranging from 50 to 500 mg.
EXAMPLE 1:1 -(4,4'-Difluorobenzhydryl)-4-(2-phenyl- 1 ,3-dioxolane-2-propyl)piperazine 14 g of N-mono-(4,4'-difluorobenzhydryl)piperazine (0.049 mol) are dissolved in 200 ml of absolute ethanol in the presence of 5.88 g of sodium bicarbonate (0.07 mol). The resulting mixture is gently treated with 13.3 g solution 2-(3-chloropropyl)-2-phenyl-1,3,-dioxolane (0.059 mol) in 50 ml of absolute ethanol, and then refluxed for 24 hours. After conditioning the reaction mass, it is filtered off and the ethanol is removed by distillation at vacuum. The residue, dissolved in n-hexane, is subjected to solicagel column chromatography (1-hour activation at 120"C) and a mixture of n-hexane and acetone is used as eluent.The eluate is concentrated up to dryness and the obtained oil crystallizes from n-hexane, yielding 9.2 g of crystals of 1-(4,4' difluorobenzyhydryl)-4-(2-phenyl- 1 ,3-dioxolane-2-propyl)piperazine. Yield 39%. M.p. 76-78"C (d).
IR (KBr), cm l: 3000-2800, 1600, 1500, 1230, 1010, 840-830, 780, 710.
EXAMPLE 2:1 -(4,4'-Difluorobenzyhydryl)-4-(2-phenyl- 1 ,3-dioxolane-2-propyl)piperazine maleate
11 g of 1-(4,4'-difluorobenzhydryl)-4-(2-phenyl-1 ,3-dioxolane-2-propyl)piperazine are dissolved in 250 ml of absolute ethanol and then treated with 1M maleic acid ethanol solution up to pH=4.0. The mixture is left to crystallize in refrigerator, yielding 8.3 g of crystals of 1-(4,4' difluorobenzhydryl)-4-(2-phenyl- 1 ,3-dioxolane-2-propyl)piperazine. Yield 61%. M.p. 190-193"C.
IR(KBr), cm 1: 3000-2400, 1700, 1600, 1575, 1350, 1220, 870, 830, 700.
Claims (5)
1. Piperazine derivative having the formula (I):
and the non-toxic addition salts thereof.
2. A process for preparing the compound according to claim 1, characterized by reacting Nmono-(4,4'-difluorobenzyhydryl)piperazine with a 2-(3-halopropyl)-2-phenyl-1 ,3-dioxolane of the general formula (III):
wherein X is chlorine or bromine, in a medium constituted by an alkanol having from 1 to 4 carbon atoms, preferably ethanol, and in the presence of a base selected from an alkaline/alkaline earth carbonate or bicarbonate, preferably sodium bicarbonate, under reflux, followed by purification under filtration, removal of solvent at vacuum and recrystallization, and if desired, the non-toxic addition salts are obtained by treating respective acids, preferably dissolved in an alkanol having from 1 to 4 carbon atoms, preferably methanol, ethanol or isopropanol.
3. Pharmaceutical composition comprising the compound according to claim 1, optionally in combination with pharmaceutically acceptable carriers and adjuvants.
4. A piperazine derivative as claimed in claim 1, substantially as hereinbefore described.
5. A process as claimed in claim 2, substantially as hereinbefore described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08501625A GB2169892B (en) | 1985-01-23 | 1985-01-23 | Piperazine derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08501625A GB2169892B (en) | 1985-01-23 | 1985-01-23 | Piperazine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8501625D0 GB8501625D0 (en) | 1985-02-27 |
GB2169892A true GB2169892A (en) | 1986-07-23 |
GB2169892B GB2169892B (en) | 1988-02-03 |
Family
ID=10573263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08501625A Expired GB2169892B (en) | 1985-01-23 | 1985-01-23 | Piperazine derivatives |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2169892B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0397031A1 (en) * | 1989-05-12 | 1990-11-14 | Ono Pharmaceutical Co., Ltd. | Novel esters of phenylalkanoic acid |
-
1985
- 1985-01-23 GB GB08501625A patent/GB2169892B/en not_active Expired
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0397031A1 (en) * | 1989-05-12 | 1990-11-14 | Ono Pharmaceutical Co., Ltd. | Novel esters of phenylalkanoic acid |
US5013734A (en) * | 1989-05-12 | 1991-05-07 | Ono Pharmaceutical Co., Ltd. | Novel esters of phenylalkanoic acid |
Also Published As
Publication number | Publication date |
---|---|
GB8501625D0 (en) | 1985-02-27 |
GB2169892B (en) | 1988-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1454251A3 (en) | Method of producing derivatives of 4-benzyl-1(2h)-phthalazinone or physiologically endured acid-additive salts thereof | |
CA1207766A (en) | Preparation of novel xanthine derivatives | |
US4904676A (en) | Amino-oxazole compounds having dopaminergic activity | |
EP0070562B1 (en) | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
US4129565A (en) | Isocarbostyril derivatives | |
US3705907A (en) | 4-(2-hydroxy)-3-aminopropoxy)-indole derivatives | |
JP3723448B2 (en) | Method for producing thiazolidinedione derivative | |
CA1074799A (en) | Process for the production of basically substituted alkoxypyridinecarboxamides | |
HUT71132A (en) | Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing | |
GB2169892A (en) | Piperazine derivatives | |
FR2689889A1 (en) | New derivatives of perhydroisoindole, and their preparation. | |
US4402981A (en) | N1 -Acyl-N2 -phenyl-diaminopropanols and pharmaceutical compositions thereof and processes for their preparation | |
EP0093945A2 (en) | 1,4-Dihydropyridine derivatives | |
EP0166331A2 (en) | Substituted phenoxyalkyl aminopropanols, process for their preparation and their use, and compositions containing these compounds | |
US4603134A (en) | Piperazine derivative and pharmaceutical composition containing the same | |
JP2848165B2 (en) | Method for producing asymmetric dihydropyridine derivatives | |
US5817815A (en) | Pharmacologically active enantiomers | |
GB1580001A (en) | Therapeutically active 1 - phenyl - 1 - methoxy - 2-aminothane derivatives | |
GB2101587A (en) | Methylenedioxybenzene derivatives. | |
JPS6245870B2 (en) | ||
US4631277A (en) | Hexahydrodibenzodioxane compounds and pharmaceutical compositions | |
US5169859A (en) | Thiazolidinone derivatives, pharmaceutical compositions containing them and process for preparing same | |
EP0002263B1 (en) | 3-trifluoromethylsulfinyl analogs of cyproheptadine, process for their preparation and pharmaceutical composition thereof | |
CA1226289A (en) | Piperazine derivative and process for its production | |
US4010161A (en) | Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3Δ-pyrazolin-4-yl)carbamates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19970123 |